Tests AXS-05 against bupropion to prevent depression returning
Compares AXS-05 with bupropion in adults whose depression responded to AXS-05.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Key facts
- Where
- Atlanta, Bellflower, Boston, Brandon, Brooklyn, Cherry Hill, Chicago, Cincinnati, Dallas, Doral, Edmond, Everett, Friendswood, Hialeah, Hickory, Jacksonville, Lafayette, Las Vegas, Memphis, Miami, Mount Kisco, New Orleans, New York, Oceanside, Oklahoma City, Orlando, Overland Park, Portland, Redlands, Riverside, Saint Charles, San Antonio, San Diego, Staten Island, Toms River, Upland, and Wichita Falls, United StatesSee the 37 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06223880, who can take part
Where in United States
- AtlantaAtlanta, United StatesTaking people
- BellflowerBellflower, United StatesTaking people
- BostonBoston, United StatesTaking people
- BrandonBrandon, United StatesTaking people
- BrooklynBrooklyn, United StatesTaking people
- Cherry HillCherry Hill, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- CincinnatiCincinnati, United StatesTaking people
- DallasDallas, United StatesTaking people
- DoralDoral, United StatesTaking people
- EdmondEdmond, United StatesTaking people
- EverettEverett, United StatesTaking people
- FriendswoodFriendswood, United StatesTaking people
- HialeahHialeah, United StatesTaking people
- HickoryHickory, United StatesTaking people
- JacksonvilleJacksonville, United StatesTaking people
- LafayetteLafayette, United StatesTaking people
- Las VegasLas Vegas, United StatesTaking people
- MemphisMemphis, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Mount KiscoMount Kisco, United StatesTaking people
- New OrleansNew Orleans, United StatesTaking people
- New YorkNew York, United StatesTaking people
- OceansideOceanside, United StatesTaking people
- Oklahoma CityOklahoma City, United StatesTaking people
- OrlandoOrlando, United StatesTaking people
- Overland ParkOverland Park, United StatesTaking people
- PortlandPortland, United StatesTaking people
- RedlandsRedlands, United StatesTaking people
- RiversideRiverside, United StatesTaking people
- Saint CharlesSaint Charles, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- Staten IslandStaten Island, United StatesTaking people
- Toms RiverToms River, United StatesTaking people
- UplandUpland, United StatesTaking people
- Wichita FallsWichita Falls, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Axsome Therapeutics, Inc.
- Trial code
- NCT06223880
- Record updated
- 23 January 2025
- Original description
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.Read full original descriptionShow less
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Inclusion: Currently meets DSM-5 criteria for diagnosis of MDD without psychotic features; Current major depressive episode of at least 4 weeks in duration.
Exclusion: Previously participated in another clinical study of AXS-05; received any investigational drug or device treatment within 30 days of (Screening) Visit 1, or has been prescribed Auvelity; Unable to comply with study procedures; Medically inappropriate for study participation in the opinion of the investigator.